Sanara MedTech (SMTI) CFO awarded 12,687 restricted shares vesting 2027-2029

Rhea-AI Filing Summary

Taylor Elizabeth B reported acquisition or exercise transactions in this Form 4 filing.

Sanara MedTech Inc. granted its Chief Financial Officer, Elizabeth B. Taylor, 12,687 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost and increase her direct holdings to 17,632 common shares following the transaction.

The restricted stock will vest in three equal installments, with one-third vesting on March 22 of 2027, 2028, and 2029, respectively. Vesting is conditioned on her continued employment with Sanara MedTech through each vesting date, aligning a portion of her compensation with the company’s long-term performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Taylor Elizabeth B

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	12,687	$0.00	--

Holdings After Transaction: Common Stock — 17,632 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Elizabeth B

(Last) (First) (Middle)

1200 SUMMIT AVE

SUITE 414

(Street)

FORT WORTH TEXAS 76102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sanara MedTech Inc. [ SMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/22/2026		A		12,687(1)	D	$0(1)	17,632	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date.

	/s/ Elizabeth B. Taylor	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Sanara MedTech (SMTI) report for its CFO?

Sanara MedTech reported that CFO Elizabeth B. Taylor received 12,687 shares of restricted common stock as an equity grant. The award was recorded as a Form 4 acquisition with no cash price per share and reflects compensation rather than an open-market purchase.

How many Sanara MedTech (SMTI) shares does the CFO hold after this Form 4?

After the restricted stock grant, CFO Elizabeth B. Taylor directly holds 17,632 shares of Sanara MedTech common stock. This total includes the newly granted 12,687 restricted shares that are subject to a multi-year vesting schedule tied to continued employment.

What are the vesting terms of the Sanara MedTech (SMTI) CFO’s restricted stock grant?

The 12,687 restricted shares granted to Sanara MedTech’s CFO vest in three equal installments. One-third vests on March 22, 2027, another third on March 22, 2028, and the final third on March 22, 2029, contingent on continued employment.

Is the Sanara MedTech (SMTI) CFO’s Form 4 transaction a market purchase or sale?

The transaction is not a market purchase or sale. It is a grant of 12,687 restricted shares recorded under code “A” for grant or award, with a price per share of 0.0000, representing stock-based compensation rather than trading in the open market.

What conditions apply to the Sanara MedTech (SMTI) CFO’s restricted stock award?

The restricted shares will vest only if the CFO remains employed by Sanara MedTech through each vesting date in 2027, 2028, and 2029. If employment ends before a scheduled vesting date, the unvested portion of the award would not vest under these terms.